The Form 4 filing, a report of insider stock trades, was filed on November 18, 2026. The sales took place one day earlier. Andrew J. Murphy is Regeneron’s Co-Chief Scientific Officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 16 |
| Shares Transacted | 5,011 |
| Price | $957.76 |
| Total Transaction Value | $4,799,336.48 |
| Insider | |
| Ticker Symbol | REGN |
| Company | REGENERON PHARMACEUTICALS, INC. |
| Insider Name | MURPHY ANDREW J |
| Insider Title | Co-Chief Scientific Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 46,779 |
| Position Size Change | 9.68% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The activity covered 16 transactions in Regeneron (REGN) shares. All of the reported sales took place on November 17, 2026.
What was the average price of the transaction?
The average sale price was $957.76 per share across the 16 transactions. Separate prices for each sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
He sold 5,011 shares and reported 46,779 shares owned afterward. Those figures put his reported balance before the sales at 51,790 shares. He sold 9.68% of that earlier balance.
What's the total transaction value?
The total reported value of the 16 sales was $4,799,336.48.
Are there any special circumstances around this transaction?
The transaction details point to a Rule 10b5-1 trading plan, which sets trading instructions in advance. The reference could apply to the filing as a whole. Footnote text was not available, so it is unclear which of the 16 sales it covers. The available information does not give a plan start date, trading schedule, or other terms.
Source: SEC Form 4.
For research purposes only; not investment advice.